报价延迟最少15分钟:2025/07/20 13:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.75/-3.64
|
|
企业价值
271.84M
|
| 资产负债 |
|
每股账面净值
0.11
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:06 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE. |
